Sirna Therapeutics, Inc.

47 articles about Sirna Therapeutics, Inc.

• 

  RNAi: The Monoclonal Antibody of the 2020s?

  8/29/2018

  There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals’ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops.

• Alnylam Pharmaceuticals Announces Closing Of Previously Announced Acquisition Of Merck & Co., Inc.'s Sirna Therapeutics, Inc. Subsidiary

  3/6/2014

• Alnylam Pharmaceuticals Ponies Up $175 Million Upfront For Merck & Co., Inc.'s Sirna Therapeutics, Inc.

  1/13/2014

• Biotech Blossoms Anew

  4/30/2008

• Protiva Biotherapeutics: California Superior Court Grants Preliminary Injunction Prohibiting Sirna Therapeutics, Inc. From Using Protiva Technology

  4/16/2007

• Sirna Therapeutics, Inc. Shareholders Approve Acquisition By Merck & Co., Inc.

  12/28/2006

• Merck & Co., Inc. And Sirna Therapeutics, Inc. Announce Expiration Of Hart-Scott-Rodino Waiting Period For The Proposed Acquisition Of Sirna By Merck

  12/14/2006

• Sirna Therapeutics, Inc. Reports Third Quarter 2006 Financial Results

  11/14/2006

• Sirna Therapeutics, Inc. To Present At 2006 Biotechnology Industry Organization (BIO) InvestorForum

  10/11/2006

• Sirna Therapeutics, Inc. To Present At UBS Warburg Global Life Sciences Conference

  9/15/2006

• Sirna Therapeutics, Inc. To Present At BioJapan 2006 World Business Forum

  9/11/2006

• Sirna Therapeutics, Inc. Reports Second Quarter 2006 Financial Results

  8/15/2006

• Sirna Therapeutics, Inc. Reports Final Results From Phase 1 Study On Its RNAi-Based Therapeutic For Age-Related Macular Degeneration

  8/10/2006

• Sirna Therapeutics, Inc. To Report Second Quarter 2006 Financial Results On August 14, 2006

  8/8/2006

• Sirna Therapeutics, Inc. To Present At Bank of America 2006 Specialty Pharmaceuticals Conference

  8/3/2006

• Sirna Therapeutics, Inc. Release: European Patent Office Significantly Limits Scope Of Kreutzer-Limmer RNAi Patent Claim

  6/23/2006

• Sirna Therapeutics, Inc. To Webcast Presentation At The Needham & Company Biotechnology And Medical Technology Conference

  6/8/2006

• Sirna Therapeutics, Inc. Announces Exercise Of Over-Allotment Option By Underwriters

  5/30/2006

• Sirna Therapeutics, Inc. Announces Pricing Of Common Stock Offering

  5/24/2006

• Sirna Therapeutics, Inc. Announces Public Offering Of Common Stock

  5/15/2006